Literature DB >> 15819592

Mycophenolate sodium delayed release: prevention of renal transplant rejection.

Monique P Curran1, Gillian M Keating.   

Abstract

Mycophenolate sodium delayed release is an enteric-coated formulation designed to release the active agent (mycophenolic acid) in the small intestine. Mycophenolate sodium delayed release was equivalent in efficacy to, and had a similar tolerability profile as, mycophenolate mofetil in de novo renal transplant patients treated with ciclosporin (cyclosporin) and corticosteroids in a well designed study of 12 month's duration. Maintenance renal transplant patients treated with ciclosporin and corticosteroids were converted from mycophenolate mofetil to mycophenolate sodium delayed release without any alteration in efficacy or tolerability in a well designed study of 12 month's duration. The incidence of gastrointestinal adverse events with mycophenolate sodium delayed release was similar to that with mycophenolate mofetil.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15819592     DOI: 10.2165/00003495-200565060-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials.

Authors:  D K Granger
Journal:  Transplant Proc       Date:  2001 Nov-Dec       Impact factor: 1.066

2.  Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts.

Authors:  Emanuele Cozzi; Conrad Vial; Daniel Ostlie; Bhatti Farah; Gilda Chavez; Kenneth G C Smith; John R Bradley; Sathia Thiru; Hugh F S Davies; John Wallwork; David J G White; Martin Goddard; Peter J Friend
Journal:  Xenotransplantation       Date:  2003-07       Impact factor: 3.907

3.  Comparative efficacy of mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) with and without cyclosporine in rat transplantation models.

Authors:  H J Schuurman; C Pally; M Fringeli-Tanner; C Papageorgiou
Journal:  Transplantation       Date:  2001-12-15       Impact factor: 4.939

4.  Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study.

Authors:  Klemens Budde; John Curtis; Gregory Knoll; Lawrence Chan; Hans-Hellmut Neumayer; Yodit Seifu; Michael Hall
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

5.  Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

Authors:  Maurizio Salvadori; Herwig Holzer; Angelo de Mattos; Hans Sollinger; Wolfgang Arns; Federico Oppenheimer; Jeff Maca; Michael Hall
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

6.  Mycophenolate mofetil: a review of its use in the management of solid organ transplantation.

Authors:  A Bardsley-Elliot; S Noble; R H Foster
Journal:  BioDrugs       Date:  1999-11       Impact factor: 5.807

7.  Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study.

Authors:  B Nashan; K Ivens; B Suwelack; W Arns; M Abbud Filho
Journal:  Transplant Proc       Date:  2004-03       Impact factor: 1.066

Review 8.  Review of the immunosuppressant enteric-coated mycophenolate sodium.

Authors:  Klemens Budde; Petra Glander; Fritz Diekmann; Johannes Waiser; Lutz Fritsche; Duska Dragun; Hans-Hellmut Neumayer
Journal:  Expert Opin Pharmacother       Date:  2004-06       Impact factor: 3.889

  8 in total
  2 in total

1.  Drug discovery from natural sources.

Authors:  Young-Won Chin; Marcy J Balunas; Hee Byung Chai; A Douglas Kinghorn
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

Review 2.  Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.